Undersøgelsen viste gavnlig effekt af memantinbehandlingen sammenlignet med placebo over en behandlingsperiode på 6 måneder (” observed cases analysis ” for the Clinician´s interview based impression of change (CIBIC- plus): p=0, 025; Alzheimer´s disease cooperative study – activities of daily living (ADCS- ADLsev): p=0, 003; Severe impairment battery (SIB): p=0, 002).
L’ étude a montré le bénéfice du traitement par la mémantine par rapport au placebo à 6 mois (analyse des cas observés pour la Clinician’ s Interview Based Impression of Change [CIBIC-plus]: p=0,025; l’ Alzheimer’ s Disease Cooperative Study-Activities of Daily Living [ADCS-ADLsev]: p=0,003; la Severe Impairment Battery [SIB]: p=0,002).